Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 1.00 |
| ▸ | CCND1 | P24385 | 19/20 | 1.00 |
| ▸ | CDK2 | P24941 | 8/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754798 | 0.93 | CDK4 (0.87) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL6753793 | 0.91 | CDK4 (0.83) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL4026307 | 0.85 | CDK4 (0.93) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL6753785 | 0.84 | CDK4 (0.74) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL6749107 | 0.84 | CDK4 (0.72) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL4026313 | 0.83 | CDK4 (1.00) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL10087379 | 0.82 | CDK4 (0.71) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL4203842 | 0.82 | CDK4 (0.80) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL6753304 | 0.82 | CDK4 (0.76) | CDK4CCND1CDK2CCNB2ABL1 | |
| SCHEMBL7664909 | 0.81 | CDK4 (0.69) | CDK4CCND1CDK2CCNB2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706718-B2 | POTENT INHIBITORS OF CYCLIN DEPENDENT KINASES; TREATING CANCER OR OTHER PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | claimed |
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| EP-4162076-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-6706718-B2 | POTENT INHIBITORS OF CYCLIN DEPENDENT KINASES; TREATING CANCER OR OTHER PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-6407103-B2 | POTENT ENZYME INHIBITORS OF CYCLIN-DEPENDENT KINASES RELATING TO THE CATALYTIC SUBUNITS CDK1-9 AND THEIR REGULATORY SUBUNITS CYCLINS A-H; ANTIPROLIFERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; VIRICIDES; MODULATORS OF DNA/RNA BIOSYNTHESIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | DUPONT PHARMACEUTICALS COMPANY | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | CDK1, CCNA1, CDK19 | CDK4 14/4885CCND1 45/4885CDK2 8/4885 |
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | CCNA1, CCNI, CDKN1A | CDK4 10/4885CCND1 34/4885CDK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.